Growth Blocker MRI Dx™
Diagnose · Map · Read · Identify
Examines 9 dimensions of your technology and product, traces every symptom through its diseases to the true root cause, and scores severity. Find what's actually wrong.
The Frameworks
Symptoms · Diagnosis · Prescription · Treatment · Recovery · Scale. One framework that runs from visible symptoms to scaled recovery — built on three connected frameworks for diagnosis, prescription and treatment. A technology diagnostic framework for CEOs to find the root causes behind slow growth, rising cost, delayed releases, weak AI ROI and platform instability.
What the CEO, board and customers actually see.
Growth Blocker MRI Dx™ across the 9 diagnostic dimensions.
Growth Accelerator Rx™ — a 30/60/90-day roadmap.
Growth Transformation Tx™ — execution in live production.
Business outcomes & health scorecard.
Operating cadence that holds the gains.
Diagnose the disease, sequence the cure, execute the recovery. Each is a proprietary, trademarked framework in its own right — and they are built to work as one.
Examines 9 dimensions of your technology and product, traces every symptom through its diseases to the true root cause, and scores severity. Find what's actually wrong.
Untangles the cyclic-dependent root causes into the only order that can work — a 30/60/90-day protocol with severity and stop / start / continue / delay. The right fix, in the right sequence.
Performs the recovery without stopping the business — across People, Process & Platform Architecture. Powered by the Chess Board Transformation Architecture™ and System Feature Matrix™ techniques.
The framework separates what the CEO sees from what is actually wrong — across three tiers. The 9 CEO-Facing Symptoms are the visible layer. Beneath them sit 78 named technology diseases across 9 families. And beneath those sit 451 named root causes — the deepest layer, where the diseases actually originate. Treatment addresses the root causes, not the symptoms.
Slow Growth · Poor CX & Quality · Architecture Not Fit for Scale · Delayed Releases · Tech Cost Rising Faster than Value · Business-Product-Tech Misalignment · Weak Tech Leadership · Missing Observability · AI Not Producing Value.
Growth & Product · Quality & Reliability · Architecture · Delivery & DevOps · Cost & FinOps · Operating Model · Leadership & Capability · Observability · AI & Data. Each disease carries its definition, signs, symptom mapping and treatment direction.
The deepest layer — 451 uniquely-named root causes mapped to the diseases above. They are cyclically dependent, which is why the prescription must untangle them into the right sequence before treatment can work.
"Cloud cost is rising" (symptom) → architecture-driven cost leakage (disease) → over-provisioned workloads · duplicated services · no cost owner (root causes). Trim instances and the cost returns; fix the architecture and it doesn't.
Most technology reviews begin with the technology stack. The Growth Blocker MRI Dx™ begins with business health and works inward through nine diagnostic dimensions.
Why is growth not moving at the expected pace? Where is technology limiting acquisition, conversion, retention or expansion?
Where is technology limiting acquisition, conversion or retention? Is the platform ready for the next growth push?
Are product decisions connected to business impact? Are teams shipping features with measurable outcomes?
Can you trace your last 10 releases to a business outcome? Are teams shipping features — or results?
Does the platform survive growth, traffic spikes, partner load and operational complexity — or only normal conditions?
Does the platform survive your next 10×? What breaks first under load?
Why is large team effort producing low business output? Where do dependencies, rework, firefighting and meetings consume velocity?
Why is a large team producing modest output? Where does the week go — building, or firefighting?
Is cost rising faster than business value? Where is over-provisioning, vendor leakage and weak FinOps discipline?
Is cost rising faster than value? Could you cut a fifth without hurting reliability — and do you know where?
Is data trusted? Are AI use cases prioritized by value? Are governance, data and workflow ready for automation?
Is your data trusted enough to act on? Are AI use-cases ranked by value, or by hype?
Are slow journeys, broken workflows, mobile/web performance or onboarding friction weakening growth and retention?
Where do customers feel friction you can't see? Are slow journeys quietly costing conversion?
Can the business see what is slow, fragile or expensive before customers do? Are logs, metrics, traces, RUM, alerts and business signals connected with clear ownership?
Do you find problems before customers do? How long does root-cause analysis actually take?
Are leadership, product, engineering, QA, data and finance operating in one rhythm — or in disconnected silos?
Do leadership, product, engineering and finance run in one rhythm — or argue from different dashboards? Who decides at the platform level?
Each of the nine dimensions is scored, severity-classified and root-cause mapped. Leadership sees, in one page, where the disease sits — and where it doesn't.
Illustrative scorecard — actual values depend on the diagnostic.
Prescription follows diagnosis. Every prescription is sequenced, severity-ranked and matched to business impact — with explicit stop / start / continue / delay calls.
Most companies don't suffer from too few initiatives — they suffer from too many in the wrong order. The prescription names what to stop before it names what to start.
Initiatives where the disease is misdiagnosed and the treatment will not help — or will make recovery harder.
Right-sequenced interventions where the root cause is now clear and the leadership cadence is ready.
Healthy work that should not be disturbed — and that the prescription explicitly protects.
Important work whose timing is wrong, dependencies are immature, or readiness is not yet present.
The treatment framework used in every transformation program — performing the recovery without stopping the business. Architecture should be evidence-driven, not fashion-driven.
Every recovery starts with the question the business is actually trying to answer — grow revenue, lift conversion, cut cost, raise reliability or ship faster — translated into measurable engineering decision criteria. No architecture decision is made without a business question answered first, so the platform is built to move a metric, not to chase a trend.
Map the real journeys and workflows the platform must serve — customer, operator and partner — end to end. The platform is sized to these journeys, not the other way around, so capacity and complexity land where the business actually needs them.
Classify every workload by latency, throughput, durability, criticality and cost shape — transactional, analytical, real-time, batch and AI-inference each have a different right answer. Classification prevents the one-size-fits-all architecture that quietly limits scale and inflates cost.
Instrument logs, metrics, traces, RUM, alerts and business signals — connected, not siloed — so platform health and business impact are visible in real time, before customers feel them. You cannot treat what you cannot see, so observability goes in before, during and after the change.
Choose the right pattern per workload — monolith, modular, service-extracted, event-driven or AI-agentic — on the evidence from classification, never on fashion. Then sequence the moves so the platform can be transformed while it is still serving the business.
Deploy in a topology that matches workload economics — cloud, region, scaling pattern, FinOps controls and vendor strategy. Cost is treated as an architecture property, not an afterthought, so reliability and unit economics improve together rather than trading off.
Recovery is never just a code change. Treatment moves on three fronts at once so the gains hold after the engagement ends.
Leadership cadence, ownership, capability uplift and an operating rhythm that keeps decisions fast and accountable.
Delivery flow, quality gates, release engineering and governance — so speed and reliability rise together.
Architecture, data, observability and cost — re-architected in live production, without stopping the business.
The three frameworks end the disease. The final two stages of the method make the gains permanent — and turn the platform back into a growth engine.
The same nine diagnostic dimensions are re-scored against the original baseline, so recovery is proven on the scorecard — not asserted. Release predictability, reliability, unit cost, customer experience and growth signals all have to move in the right direction before the engagement is called a success.
An operating cadence — OKRs, quarterly planning, decision forums and observability-led reviews — locks in the recovery so the disease does not return. The platform keeps compounding as the business grows, instead of slipping back into the next round of symptoms.
A generic audit lists what exists. The Dx explains why it is limiting growth and what to do about it.
There is no tooling, vendor or partner being sold inside the diagnostic. The prescription is independent.
Microservices, AI agents, serverless and event mesh are chosen only when evidence supports them — not by reputation.
A structured way to find why technology is limiting growth, rather than a checklist audit. The Growth Blocker MRI Dx™ examines nine dimensions, traces each visible symptom through 78 named diseases to 451 root causes, and grades severity — so the diagnosis points to a cause, not just a finding.
An audit checks tools and controls against a checklist. A diagnosis traces visible business symptoms to the underlying disease and root cause, sequences the fix by dependency, and ties every item to business impact — stop, start, continue or delay.
The Growth Accelerator Rx™ output: stabilise in the first 30 days, correct execution by 60, and address structural fixes by 90. Every item is a stop/start/continue/delay decision tied to a measurable business outcome and sequenced by severity and dependency.
That is exactly what diagnosing across nine dimensions and severity-grading each is for. The root-cause tree shows which dimension is actually driving a symptom and which are downstream effects — so you treat the cause, not the loudest complaint.
Yes. The Technology Health Scorecard and root-cause map are board-ready and are frequently used for technology due diligence, value-creation planning, and go/no-go decisions ahead of investment or acquisition.
A 60–90 minute call is the fastest way to know whether the Growth Blocker MRI Dx™ is right for your situation.
Diagnosing and Treating Technology Diseases That Limit Business Growth.